Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy.

Graff, Julie N; Stein, Mark N; Surana, Rishi; Al Rabadi, Luai; Liu, Eric; Fong, Lawrence; Bailey, Shawna; Latour, Emile; Newby, Timothy A; Moran, Amy E; Beer, Tomasz M

Graff, Julie N; Stein, Mark N; Surana, Rishi; Al Rabadi, Luai; Liu, Eric; Fong, Lawrence; Bailey, Shawna; Latour, Emile; Newby, Timothy A; Moran, Amy E; Beer, Tomasz M.

Afiliação

Graff JN; VA Portland Health Care System, Portland, OR, United States.
Stein MN; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
Surana R; Columbia University Medical Center, New York, NY, United States.
Al Rabadi L; MD Anderson, Houston, TX, United States.
Liu E; VA Portland Health Care System, Portland, OR, United States.
Fong L; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
Bailey S; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Latour E; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Newby TA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
Moran AE; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
Beer TM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.

Front Oncol ; 10: 1381, 2020.

Article em En | MEDLINE | ID: mdl-32850444

Palavras-chave

CTLA-4; checkpoint inhibitor; immunotherapy; metastatic; prostate cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google